Effect of bilateral oophorectomy on women's long-term health

Women's Health

Volumn 5, Issue 5, 2009, Pages 565-576

  Parker, William H ^a,d,e   Jacoby, Vanessa ^b,f   Shoupe, Donna ^g   Rocca, Walter ^c  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Parker Rosenman Rodi Gynecology Group   (United States)

^f Women's Hlth Clin Research Center   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Dementia; Depression; Estrogen deficiency; Heart disease; Hysterectomy; Menopause; Oophorectomy; Osteoporosis; Ovarian cancer; Ovarian conservation; Ovaries; Parkinsonism; Stroke; Women's health; Women's sexuality

Indexed keywords

ESTROGEN;

ANXIETY; BREAST CANCER; CARDIOVASCULAR RISK; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; ESTROGEN DEFICIENCY; FEMALE; HIP FRACTURE; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MOOD CHANGE; MORTALITY; OBSERVATIONAL STUDY; OSTEOPOROSIS; OVARIECTOMY; OVARY CANCER; OVARY DISEASE; PARKINSONISM; PATIENT SELECTION; POSTMENOPAUSE; PREMENOPAUSE; QUALITY OF LIFE; REVIEW; SALPINGOOOPHORECTOMY; STROKE; UNITED STATES; WOMEN'S HEALTH; AFFECT; COMPLICATION; DECISION MAKING; HEALTH STATUS; HIP FRACTURES; MIDDLE AGED; OVARY; PROCEDURES; RISK ASSESSMENT; SEXUALITY; SURGERY; TIME; TREATMENT OUTCOME;

AFFECT; DECISION MAKING; FEMALE; HEALTH STATUS; HIP FRACTURES; HUMANS; HYSTERECTOMY; MIDDLE AGED; OSTEOPOROSIS; OVARIECTOMY; OVARY; QUALITY OF LIFE; RISK ASSESSMENT; SEXUALITY; TIME FACTORS; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 69849090216     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.09.42     Document Type: Review

References (106)

1. Judd H, Judd G, Lucas W, Yen S: Endocrine function of the postmentopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J. Clin. Endocrinol. Metab. 39, 1020-1024 (1974).
2. Fogle R, Stanczyk F, Zhang X, Paulson R: Ovarian androgen production in postmenopausal women. J. Clin. Endocrinol. Metab. 92, 3040-3043 (2007).
3. Meldrum D, Davidson B, Tataryn I, Judd H: Changes in circulating steroids with aging in postmenopausal women. Obstet. Gynecol. 57, 624-628 (1981).
4. Colditz G, Willett W, Stampfer M, Rosner B, Speizer F, Hennekens C: Menopause and the risk of coronary heart disease in women. N. Engl. J. Med. 316, 1105-1110 (1987).
5. Atsma, F, Bartelink, M, Grobbee D, van der Schouw Y: Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 13, 265-279 (2006).
6. Rocca W, Bower J, Maraganore D et al.: Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69, 1074-1083 (2007).
7. Rocca W, Bower JH, Maraganore D et al.: Increased risk of Parkinsonism in women who underwent oophorectomy before menopause. Neurology 70(3), 200-209 (2008).
8. Rocca W, Grossardt B, Geda Y et al.: Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy. Menopause 15, 1050-1059 (2008).
9. Bennett D: Editorial Comment on 'Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study' by Plassman et al. Neuroepidemiology 29, 133-135 (2007).
10. Holub Z, Jandourek M, Jabor A, Kliment L, Wagnerova M: Does hysterectomy without salpingo-oophorectomy influence the reoperation rate for adnexal pathology? A retrospective study. Clin. Exp. Obstet. Gynecol. 27, 109-112 (2000).
11. Dekel A, Efrat Z, Orvieto R et al.: The residual ovary syndrome: a 20-year experience. Eur. J. Obst. Gynecol. Reprod. Biol. 68, 159-164 (1996).
12. Armstrong K, Schwartz J, Randall T, Rubin S, Weber B: Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision ana lysis. J. Clin. Oncol. 22, 1045-1054 (2004).
13. Olive D: Dogma, skepsis, and the analytic method: the role of prophylactic oophorectomy at the time of hysterectomy. Obstet. Gynecol. 106, 214-215 (2005).
14. Jemal A, Siegel R, Ward E et al.: Cancer statistics 2008. CA Cancer J. Clin. 58, 71-96 (2008).
15. Quaye L, Gayther SA, Ramus SJ et al.: The effects of common genetic variants in oncogenes on ovarian cancer survival. Clin. Cancer Res. 14(18), 5833-5839 (2008).
16. Legge F, Ferrandina G, Salutari V, Scambia G: Biological characterization of ovarian cancer: prognostic and therapeutic implications. Ann. Oncol. 16(Suppl. 4), 95-101 (2005).
17. Hartge P, Whittemore AS, Itnyre J, McGowan L, Cramer D: Rates and risks of ovarian cancer in subgroups of White women in the United States: The Collaborative Ovarian Cancer Group. Obstet. Gynecol. 84, 760-764 (1994).
18. Sightler SE, Boike GM, Estape RE, Averette HE: Ovarian cancer in women with prior hysterectomy: a 14-year experience at the University of Miami. Obstet. Gynecol. 78, 681-684 (1991).
19. Rozario D, Brown I, Fung MF, Temple L: Is incidental prophylactic oophorectomy an acceptable means to reduce the incidence of ovarian cancer? Am. J. Surg. 173, 495-498 (1997).
20. Bailey CL, Ueland FR, Land GL et al.: The malignant potential of small cystic ovarian tumors in women over 50 years of age. Gynecol. Oncol. 69(1), 3-7 (1998).
21. Naylor AC: Hysterectomy - ana lysis of 2901 personally performed procedures. S. Afr. Med. J. 65, 242-245 (1984).
22. Christ JE, Lotze EC: The residual ovary syndrome. Obstet. Gynecol. 46, 551-556 (1975).
23. Kreiger N, Sloan M, Cotterchio M, Kirsh V: The risk of breast cancer following reproductive surgery. Eur. J. Cancer 35, 97-101 (1999).
24. Schairer C, Persson I, Falkeborn M, Naessen T, Troisi R, Brinton LA: Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int. J. Cancer 70, 150-154 (1997).
25. Parazzini F, Braga C, La Vecchia C, Negri E, Acerboni S, Franceschi S: Hysterectomy, oophorectomy in premenopause, and risk of breast cancer. Obstet. Gynecol. 90, 453-456 (1997).
26. Irwin KL, Lee NC, Peterson HB, Rubin GL, Wingo PA, Mandel MG: Hysterectomy, tubal sterilization, and the risk of breast cancer. Am. J. Epidemiol. 127, 1192-1201 (1988).
27. Brinton LA, Schairer C, Hoover RN, Fraumeni JF Jr: Menstrual factors and risk of breast cancer. Cancer Invest 6, 245-254 (1988).
28. Van der Schouw Y, van der Graa Y, Steyerberg E, Eijkemans M, Banga J: Age at menopause as a risk factor for cardiovascular mortality. Lancet 347, 714-718 (1996).
29. Løkkegaarda E, Jovanovicb Z, Heitmannc B, Keidingb N, Ottesend B, Pedersend A: The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas 53, 226-233 (2006).
30. de Kleijn MJ, van der Schouw YT, Verbeek AL, Peeters PH, Banga JD, van der Graaf Y: Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am. J. Epidemiol. 155, 339-345 (2002).
31. Colditz G, Manson J, Hankinson S: The Nurses' Health Study: 20 year contribution to the understanding of health among women. J. Womens Health 6, 49-62 (1997).
32. Falkeborn M, Schairer C, Naessen T, Persson I: Risk of myocardial infarction after oophorectomy and hysterectomy. J. Clin. Epidemiol. 53, 832-837 (2000).
33. Jacoby VL, Grady D, Sawaya GF: Oophorectomy as a risk factor for coronary heart disease. Am. J. Obstet. Gynecol. 200, 140 (2009).
34. Ritterband A, Jaffe I, Densen P, Magagna J, Reed E: Gonadal function and the development of coronary heart disease. Circulation 27, 237-251 (1963).
35. Gordon T, Kannel W, Hjortland M, McNamara P: Menopause and coronary heart disease: The Framingham Study. Ann. Intern. Med. 89, 157-161 (1978).
36. Palmer J, Rosenberg L, Shapiro S: Reproductive factors and risk of myocardial infarction. Am. J. Epidemiol. 136, 408-416 (1992).
37. Howard B, Kuller L, Langer R et al.: Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study. Circulation 111, 1462-1470 (2005).
38. Svanberg L: Effects of estrogen deficiency in women castrated when young. Acta Obstet. Gynecol. Scand. Suppl. 106, 11-15 (1981).
39. Luoto T, Kaprio J, Reunanen A, Rutanen E: Cardiovascular morbidity in relation to ovarian function after hysterectomy. Obstet. Gynecol. 85, 515-522 (1995).
40. Rocca W, Grossardt B, de Andrade M, Malkasian G, Melton J: Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 7, 821-828 (2006).
41. Hsia J, Barad D, Margolis K et al.: Usefulness of prior hysterectomy as an independent risk predictor of Framingham risk score (the Women's Health Initiative). Am. J. Cardiol. 92, 264-269 (2003).
42. Cheung L, Pang M, Lam C, Tomlinson B, Chung T, Haines C: Acute effects of a surgical menopause on serum concentrations of lipoprotein(a). Climacteric 1, 33-41 (1998).
43. Mihmanli V, Mihmanli I, Kantarci F, Aydin T, Yilmaz M, Ogut G: Carotid pulsatility indices in surgical menopause. Arch. Gynecol. Obstet. 266, 96-100 (2002).
44. Hodis H, Mack W: Atherosclerosis imaging methods: assessing cardiovascular disease and evaluating the role of estrogen in the prevention of atherosclerosis. Am. J. Cardiol. 89, 19E-27E (2002).
45. Mack W, Slater C, Xiang M, Shoupe D, Lobo R, Hodis H: Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertil. Steril. 82, 391-397 (2004).
46. Khatibi A, Agardh C, Shakir Y et al.: Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women: The Women's Health in the Lund Area (WHILA) Study. Climacteric 10, 386-392 (2007).
47. Bushnell CD, Hurn P, Colton C et al.: Advancing the study of stroke in women: summary and recommendations for future research from an NINDS-Sponsored Multidisciplinary Working Group. Stroke 37, 2387-2399 (2006).
48. Raisz RK, Wilta B, Artis A et al.: Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J. Clin. Endocrinol. Metab. 81, 37-43 (1996).
49. Kreiger N, Kelsey J, Holford TR, O'Connor T: An epidemiologic study of hip fracture in postmenopausal women. Am. J. Epidemiol. 116, 141-148 (1982).
50. Burger HG, Dudley EC, Cui J et al.: A prospective study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J. Clin. Endocrinol. Metab. 85, 2832-2838 (2000).
51. Laughlin GA, Barett-Connor E, Kritz-Silverstein D, von Muhlen D: Hysterectomy, oophorectomy and endogenous sex hormone levels in older women: The Rancho Bernardo Study. J. Clin. Endcrinol. Metab. 85(2), 645-651 (2000).
52. Davison SL, Bell R, Donath S, Montalto JF, Davis SR: Androgen levels in adult females: changes with age, menopause, and oophorectomy. J. Clin. Endocrinol. Metab. 90, 3847-3853 (2005).
53. Johansson C, Mellstrom D, Milsom I: Reproductive factors as predictors of bone density and fractures in women at age 70. Maturitas 17, 39-50 (1993).
54. Davidson BJ, Ross RK, Paganini-Hill A, Hammond GD, Siiteri PK, Judd HL: Total and free estrogens and androgens in postmenopausal women with hip fractures. J. Clin. Endocrinol. Metab. 54, 115-120 (1982).
55. Cummings S, Browner W, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B: Endogenous hormones and the risk of hip and vertebral fractures among older women. N. Engl. J. Med. 339, 733-738 (1998).
56. Melton J, Khosla S, Malkasian GD, Achenbach SJ, Oberg AL, Riggs BL: Fracture risk after bilateral oophorectomy in elderly women. J. Bone Miner. Res. 18, 900-905 (2003).
57. Kritz-Silverstein D, von Mühlen D, Barrett-Connor E: Hysterectomy and oophorectomy are unrelated to bone loss in older women. Maturitas 47, 61-69 (2004).
58. Antoniucci DM, Sellmeyer DE, Cauley JA et al.; Study of Osteoporotic Fractures Research Group: Postmenopausal bilateral oophorectomy is not associated with increased fracture risk in older women. J. Bone Miner. Res. 20, 741-747 (2005).
59. Ohta H, Makitab K, Komukaib S, Nozawab S: Bone resorption versus estrogen loss following oophorectomy and menopause. Maturitas 43, 27-33 (2002).
60. Keene G, Parker M, Pryor G: Mortality and morbidity after hip fractures. BMJ 13, 1248-1250 (1993).
61. Center J, Nguyen T, Schneider D, Sambrook P, Eisman J: Mortality after all major types of ostoporotic fracture in men and women: an observational study. Lancet 353, 878-882 (1999).
62. Nathorst-Boos J, von Schoultz B, Carlstrom K: Elective ovarian removal and estrogen replacement therapy-effects on sexual life, psychological well-being and androgen status. J. Psychosom. Obstet. Gynaecol. 14(4), 283-293 (1993).
63. Nieman L: Management of surgically hypogonadal patients unable to take sex hormone replacement therapy. Endocrinol. Metab. Clin. North Am. 32, 325-336 (2003).
64. Shifren J: Androgen deficiency in the oophorectomized woman. Fertil. Steril. 77(Suppl 4), S60-S62 (2002).
65. Sherwin B, Gelfan M: The role of androgens in the maintenance of sexual functioning in oophorectomized women. Psychosom. Med. 49, 397-409 (1978).
66. Gallicchio L, Whiteman M, Tomic D, Miller K, Langenberg P, Flaws J: Type of menopause, patterns of hormone therapy use, and hot flashes. Fertil. Steril. 85, 1432-1440 (2006).
67. Hansen K: Female Reproductive Biology in the Physiologic Basis of Surgery. O'Leary P, Tabuenca A, Capote LR (Eds). Lippincott Williams and Wilkins, PA, USA 314-315 (2007).
68. Gallicchio L, Whiteman MK, Tomic D, Miller KP, Langenberg P, Flaws JA: Type of menopause, patterns of hormone therapy use, and hot flashes. Fertil. Steril. 85(5), 1432-1440 (2006).
69. Farrag A, Khedr E, Abdel-Aleem H, Rageh T: Effect of surgical menopause on cognitive functions. Demet. Geriatr. Cogn. Disord. 13(3), 193-198 (2002).
70. Sherwin B: Surgical menopause, estrogen and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 13, 345-357 (1988).
71. Bachmann GA, Nevadunsky NS: Diagnosis and treatment of atrophic vaginitis. Am. Fam. Physician 61(10), 3090-3096 (2000).
72. Lieblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L: Vaginal atrophy in the postmenopausal woman: the importance of sexual activity and hormones. JAMA 249, 2195-2198 (1983).
73. Schifren J, Braustein G, Simon J et al.: Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med. 343, 682-688 (2000).
74. Elit l, Esplen M, Butler K, Narod S: Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam. Cancer 1, 149-156 (2001).
75. Sherwin BB, Gelfan MM: The role of androgens in the maintenance of sexual functioning in oophorectomized women. Psychosom. Med. 49, 397-409 (1978).
76. Teplin V, Vittinghoff E, Lin F, Learman L, Richter H, Kuppermann M: Oophorectomy in premenopausal women: health-related quality of life and sexual functioning. Obstet. Gynecol. 109, 347-354 (2007).
77. Parker W, Broder M, Liu Z, Shoupe D, Farquhar C, Berek J: Ovarian conservation at the time of hysterectomy for benign disease. Obstet. Gynecol. 106, 219-226 (2005).
78. Rivera C, Grossardt B, Rhodes D, Rocca W: Increased mortality for neurological and mental diseases following early bilateral oophorectomy. Neuroepidemiology 33, 32-40 (2009).
79. Parker WH, Broder MS, Chang E et al.: Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses' Health Study. Obstet. Gynecol. 113, 1027-1037 (2009).
80. Wegienka G, Havstad S, Kelsey J: Menopausal hormone therapy in a health maintenance organization before and after Women's Health Initiative hormone trials termination. J. Womens Health (Larchmt) 15, 369-378 (2006).
81. Aziz A, Bergquist C, Brannstrom M, Nordholm L, Silfverstolpe G: Differences in aspects of personality and sexuality between perimenopausal women making different choices regarding prophylactic oophorectomy at elective hysterectomy. Acta Obstet. Gynecol. Scand. 84, 854-859 (2005).
82. Shifren JL, Avis NE: Surgical menopause: effects on psychological well-being and sexuality. Menopause 14, 586-591 (2007).
83. Ragonese P, D'Amelio M, Salemi G et al.: Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology 62, 2010-2014 (2004).
84. Ascherio A, Chen H, Schwarzschild M, Zhang S, Colditz G, Speizer F: Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 60, 790-795 (2003).
85. McEwen B, Alves S: Estrogen actions in the central nervous system. Endocr. Rev. 20, 279-307 (1999).
86. Monk D, Brodaty H: Use of estrogens for the prevention and treatment of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 11, 1-10 (2000).
87. Gibbs R, Aggarwal P: Estrogen and basal forebrain cholinergic neurons: implications for brain aging and Alzheimer's disease-related cognitive decline. Horm. Behav. 34, 98-111 (1998).
88. Markowska AL, Savonenko AV: Effectiveness of estrogen replacement in restoration of cognitive function after long-term estrogen withdrawal in aging rats. J. Neurosci. 22, 10985-10995 (2002).
89. Xu H, Gouras G, Greenfield J et al.: Estrogen reducesneuronal generation of Alzheimer β-amyloid peptides. Nat. Med. 4, 447-451 (1998).
90. Huang J, Guan H, Booze R, Eckman C, Hersh L: Estrogen regulates neprilysin activity in rat brain. Neurosci. Lett. 367, 85-87 (2004).
91. Chen S, Nilsen J, Brinton RD: Dose and temporal pattern of estrogen exposure determines neuroprotective outcome in hippocampal neurons: therapeutic implications. Endocrinology 147, 5303-5313 (2006).
92. Morrison JH, Brinton RD, Schmidt PJ, Gore AC: Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women. J. Neurosci. 26, 10332-10348 (2006).
93. Yaffe K, Sawaya G, Lieberburg I, Grady D: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 279, 688-695 (1998).
94. LeBlanc E, Janowsky J, Chan B, Nelson H: Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 285, 1489-1499 (2001).
95. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J: The nature of the effect of female gonadal hormone replacement therapy on cognitive function in postmenopausal women: a meta-analysis. Neuroscience 101, 485-512 (2000).
96. Shumaker S, Legault C, Rapp S et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289, 2651-2662 (2003).
97. Rapp S, Espeland M, Shumaker S et al.: Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289, 2663-2672 (2003).
98. Espeland M, Rapp S, Shumaker S et al.: Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291, 2959-2968 (2004).
99. Shumaker S, Legault C, Kuller L et al.: Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291, 2947-2958 (2004).
100. Resnick S, Henderson V: Hormone therapy and risk of Alzheimer disease: a critical time. JAMA 288, 2170-2172 (2002).
101. Henderson V, Benke K, Green R, Cupples L, Farrer L: Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J. Neurol. Neurosurg. Psychiatry 76, 103-105 (2005).
102. Zandi P, Carlson M, Plassman B et al.: Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 288, 2123-2129 (2002).
103. Siegfried T: Neuroscience: it's all in the timing. Nature 445, 359-361 (2007).
104. Kritz-Silverstein D, Barrett-Connor E: Hysterectomy, oophorectomy, and cognitive function in older women. J. Am. Geriatr. Soc. 50, 55-61 (2002).
105. Nappi R, Sinforiani E, Mauri M, Bono G, Polatti F, Nappi G: Memory functioning at menopause: impact of age in ovariectomized women. Gynecol. Obstet. Invest. 47, 29-36 (1999).
106. Orozco L, Salazar A, Clarke J, Tristan M: Hysterectomy versus hysterectomy plus oophorectomy for premenopausal women. Cochrane Database of Syst. Rev. (3), CD005638 (2008).